Bacteria-Based Nanoprobes for Cancer Therapy

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a Phase 2 single-arm study. Lancet Oncol. 2016;17(3):287–298. doi:10.1016/S1470-2045(15)00167-9
   PubMed Web of Science ®Google Scholar
• Li H, Jin H, Wan W, Wu C, Wei L. Cancer nanomedicine: mechanisms, obstacles and strategies. Nanomedicine. 2018;13(13):1639–1656. doi:10.2217/nnm-2018-0007
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2002;346(2):92–98. doi:10.1056/NEJMoa011954
   PubMed Web of Science ®Google Scholar
• Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol. 2005;6(2):93–102. doi:10.1016/S1470-2045(05)01735-3
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.
   PubMed Web of Science ®Google Scholar
• Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21(5):797–802. doi:10.1021/bc100070g
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Turkbey B, Watanabe R, Choyke PL. Cancer drug delivery: considerations in the rational design of nanosized bioconjugates. Bioconjug Chem. 2014;25(12):2093–2100. doi:10.1021/bc500481x
   PubMed Web of Science ®Google Scholar
• Wu C, Li H, Zhao H, et al. Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery. Nanoscale Res Lett. 2014;9(1):9–12. doi:10.1186/1556-276X-9-447
   PubMedGoogle Scholar
• Bar-Zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updat. 2017;31:15–30. doi:10.1016/j.drup.2017.05.002
   PubMed Web of Science ®Google Scholar
• Choi JH, Ha T, Shin M, Lee SN, Choi JW. Nanomaterial-based fluorescence resonance energy transfer (Fret) and metal-enhanced fluorescence (mef) to detect nucleic acid in cancer diagnosis. Biomedicines. 2021;9(8):928. doi:10.3390/biomedicines9080928
   PubMed Web of Science ®Google Scholar
• Li M, Zhao G, Su WK, Shuai Q. Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery. Front Chem. 2020;8:1–20. doi:10.3389/fchem.2020.00001
   PubMed Web of Science ®Google Scholar
• Guo X, Shi C, Wang J, Di S, Zhou S. PH-triggered intracellular release from actively targeting polymer micelles. Biomaterials. 2013;34(18):4544–4554. doi:10.1016/j.biomaterials.2013.02.071
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312–3322. doi:10.1200/JCO.2001.19.14.3312
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–7803. doi:10.1200/JCO.2005.04.937
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):1–12. doi:10.1038/natrevmats.2016.14
   Web of Science ®Google Scholar
• Christopher AMLS M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Physiol Behav. 2016;176:100–106.
   Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664. doi:10.1038/nrclinonc.2010.139
   PubMed Web of Science ®Google Scholar
• Li C, Zhang J, Zu YJ, et al. Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals. Chin J Nat Med. 2015;13(9):641–652. doi:10.1016/S1875-5364(15)30061-3
   PubMed Web of Science ®Google Scholar
• Zhao X, Xie N, Zhang H, Zhou W, Ding J. Bacterial Drug Delivery Systems for Cancer Therapy: “Why” and “How”. Pharmaceutics. 2023;15(9):2214. doi:10.3390/pharmaceutics15092214
   PubMed Web of Science ®Google Scholar
• Yue Y, Xu J, Li Y, et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat Biomed Eng. 2022;6(7):898–909. doi:10.1038/s41551-022-00886-2
   PubMed Web of Science ®Google Scholar
• Harimoto T, Hahn J, Chen YY, et al. A programmable encapsulation system improves delivery of therapeutic bacteria in mice. Nat Biotechnol. 2022;40(8):1259–1269. doi:10.1038/s41587-022-01244-y
   PubMedGoogle Scholar
• Thomas SC, Madaan T, Kamble NS, Siddiqui NA, Pauletti GM, Kotagiri N. Engineered Bacteria Enhance Immunotherapy and Targeted Therapy through Stromal Remodeling of Tumors. Adv Healthc Mater. 2022;11(2):e2101487. doi:10.1002/adhm.202101487
   PubMed Web of Science ®Google Scholar
• Van Mellaert L, Barbé S, Anné J. Clostridium spores as anti-tumour agents. Trends Microbiol. 2006;14(4):190–196. doi:10.1016/j.tim.2006.02.002
   PubMed Web of Science ®Google Scholar
• Coley WB. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891;14:199–220. doi:10.1097/00000658-189112000-00015
   PubMedGoogle Scholar
• Loughlin KR, William B. Coley: his Hypothesis, His Toxin, and the Birth of Immunotherapy. Urol Clin North Am. 2020;47(4):413–417. doi:10.1016/j.ucl.2020.07.001
   PubMed Web of Science ®Google Scholar
• Tsung K, Norton JA. Lessons from Coley’s Toxin. Surg Oncol. 2006;15(1):25–28. doi:10.1016/j.suronc.2006.05.002
   PubMed Web of Science ®Google Scholar
• Pearl R. Cancer and Tuberculosis. Am J Hyg. 1929;9:97–159.
   Google Scholar
• Lj OLD, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959;184(4682):291–292. doi:10.1038/184291a0
   Web of Science ®Google Scholar
• Zbar B, Bernstein ID, Rapp HJ, Branch B. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971;46(4):831–839.
   PubMedGoogle Scholar
• Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38–42. doi:10.1016/S0022-5347(17)55282-9
   PubMed Web of Science ®Google Scholar
• DeKernion JB, Huang MY, Lindner A, Smith RB, Kaufman JJ. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin. J Urol. 1985;133(4):598–600. doi:10.1016/S0022-5347(17)49104-X
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11–31. doi:10.1038/nrclinonc.2016.60
   PubMed Web of Science ®Google Scholar
• Sambasivarao SV. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2013;18:1199–1216.
   Google Scholar
• Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017;36(4):439–445. doi:10.1038/onc.2016.225
   PubMed Web of Science ®Google Scholar
• Vaupel P, Multhoff G, Vaupel P, Multhoff G. Hypoxia-/HIF-1α-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression. Oxyg Transp Tissue XL. 2018;171–175.
   Google Scholar
• Heldin CH, Rubin K, Pietras K, Östman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–813. doi:10.1038/nrc1456
   PubMed Web of Science ®Google Scholar
• Leschner S, Westphal K, Dietrich N, et al. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-α. PLoS One. 2009;4(8):e6692. doi:10.1371/journal.pone.0006692
   PubMed Web of Science ®Google Scholar
• Forbes NS, Munn LL, Fukumura D, Jain RK. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res. 2003;63(17):5188–5193.
   PubMed Web of Science ®Google Scholar
• Jivrajani M, Nivsarkar M. Ligand-targeted bacterial minicells: futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells. Nanomedicine. 2016;12(8):2485–2498. doi:10.1016/j.nano.2016.06.004
   PubMed Web of Science ®Google Scholar
• Granato ET, Meiller-Legrand TA, Foster KR. The Evolution and Ecology of Bacterial Warfare. Curr Biol. 2019;29(11):R521–37. doi:10.1016/j.cub.2019.04.024
   PubMed Web of Science ®Google Scholar
• Baindara P, Mandal SM. Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics. Biochimie. 2020;177:164–189. doi:10.1016/j.biochi.2020.07.020
   PubMed Web of Science ®Google Scholar
• Kang SR, Nguyen DH, Yoo SW, Min JJ. Bacteria and bacterial derivatives as delivery carriers for immunotherapy. Adv Drug Deliv Rev. 2022;181:114085. doi:10.1016/j.addr.2021.114085
   PubMed Web of Science ®Google Scholar
• Farkas-Himsley H, Hill R, Rosen B, Arab S, Lingwood CA. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci U S A. 1995;92(15):6996–7000. doi:10.1073/pnas.92.15.6996
   PubMed Web of Science ®Google Scholar
• Lancaster LE, Wintermeyer W, Rodnina MV. Colicins and their potential in cancer treatment. Blood Cells Mol Dis. 2007;38(1):15–18. doi:10.1016/j.bcmd.2006.10.006
   PubMed Web of Science ®Google Scholar
• Stachowiak R, Lyzniak M, Budziszewska BK, et al. Cytotoxicity of bacterial metabolic products, including listeriolysin O, on leukocyte targets. J Biomed Biotechnol. 2012;2012:1–9. doi:10.1155/2012/954375
   PubMedGoogle Scholar
• Lai XH, Arencibia I, Johansson A, et al. Cytocidal and Apoptotic Effects of the ClyA Protein from Escherichia coli on Primary and Cultured Monocytes and Macrophages. Infect Immun. 2000;68(7):4363–4367. doi:10.1128/IAI.68.7.4363-4367.2000
   PubMed Web of Science ®Google Scholar
• Barak Y, Schreiber F, Thorne SH, Contag CH, deBeer D, Matin A. Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing. BMC Cancer. 2010;10(1). doi:10.1186/1471-2407-10-146
   PubMedGoogle Scholar
• Williams EL, Djamgoz MBA. Nitric oxide and metastatic cell behaviour. BioEssays. 2005;27(12):1228–1238. doi:10.1002/bies.20324
   PubMed Web of Science ®Google Scholar
• Liu X, Yin S, Chen Y, et al. LPS-induced proinflammatory cytokine expression in human airway epithelial cells and macrophages via NF-κB, STAT3 or AP-1 activation. Mol Med Rep. 2018;17:5484–5491.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350(6264):1084–1089. doi:10.1126/science.aac4255
   PubMed Web of Science ®Google Scholar
• Huang X, Pan J, Xu F, et al. Bacteria-Based Cancer Immunotherapy. Adv Sci. 2021;8:1–22.
   Web of Science ®Google Scholar
• Bouzari S, Bakhtiari R, Ajoudanifar H, Sadat Shandiz SA. Review of the Effects of Probiotics and Their Metabolites in the Treatment of Liver Cancer: an Update on Probiotics as a New Treatment. Erciyes Med J. 2023;45:8–18.
   Web of Science ®Google Scholar
• Li Z, Wang Y, Liu J, et al. Chemically and Biologically Engineered Bacteria-Based Delivery Systems for Emerging Diagnosis and Advanced Therapy. Adv Mater. 2021;33(38):e2102580. doi:10.1002/adma.202102580
   PubMed Web of Science ®Google Scholar
• Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev. 2005;19(22):2645–2655. doi:10.1101/gad.1299905
   PubMed Web of Science ®Google Scholar
• Feng Q, Ma X, Cheng K, et al. Engineered Bacterial Outer Membrane Vesicles as Controllable Two-Way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy. Adv Mater. 2022;34:e2206200. doi:10.1002/adma.202206200
   PubMed Web of Science ®Google Scholar
• Hajam IA, Dar PA, Won G, Lee JH. Bacterial Ghosts as Adjuvants: mechanisms and Potential. Vet Res. 2017;48(1):37. doi:10.1186/s13567-017-0442-5
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez C, Moreno VM, Vallet-Regí M. Bacteria-Assisted Transport of Nanomaterials to Improve Drug Delivery in Cancer Therapy. Nanomaterials. 2022;12(2):288. doi:10.3390/nano12020288
   Web of Science ®Google Scholar
• Yin T, Diao Z, Blum NT, Qiu L, Ma A, Huang P. Engineering Bacteria and Bionic Bacterial Derivatives with Nanoparticles for Cancer Therapy. Small. 2022;18(12):e2104643. doi:10.1002/smll.202104643
   PubMed Web of Science ®Google Scholar
• Germanier R, Fuerer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975;131(5):553–558. doi:10.1093/infdis/131.5.553
   PubMed Web of Science ®Google Scholar
• Lin IYC, Van TTH, Smooker PM. Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery. Vaccines. 2015;3(4):940–972. doi:10.3390/vaccines3040940
   Google Scholar
• Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFa induction retain tumor-targeting in vivo. Nat Biotechnol. 1999;17(1):37–41. doi:10.1038/5205
   PubMed Web of Science ®Google Scholar
• Zhao M, Yang M, Ma H, et al. Targeted Therapy with a Salmonella Typhimurium Leucine-Arginine Auxotroph Cures Orthotopic Human Breast Tumors in Nude Mice. Cancer Res. 2006;66(15):7647–7652. doi:10.1158/0008-5472.CAN-06-0716
   PubMed Web of Science ®Google Scholar
• Fàbrega A, Vila J. Salmonella enterica serovar Typhimurium skills to succeed in the host: virulence and regulation. Clin Microbiol Rev. 2013;26(2):308–341. doi:10.1128/CMR.00066-12
   PubMed Web of Science ®Google Scholar
• Li CX, Yu B, Shi L, et al. ‘obligate‘anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice. Oncol Lett. 2017;13(1):177–183. doi:10.3892/ol.2016.5453
   PubMed Web of Science ®Google Scholar
• Clairmont C, Lee KC, Pike J, et al. Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of Salmonella typhimurium. J Infect Dis. 2000;181(6):1996–2002. doi:10.1086/315497
   PubMed Web of Science ®Google Scholar
• Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A. 2005;102(3):755–760. doi:10.1073/pnas.0408422102
   PubMed Web of Science ®Google Scholar
• Kimura H, Zhang L, Zhao M, et al. Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif. 2010;43(1):41–48. doi:10.1111/j.1365-2184.2009.00652.x
   PubMed Web of Science ®Google Scholar
• Nagakura C, Hayashi K, Zhao M, et al. Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res. 2009;29(6):1873–1878.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Zhao M, Yamauchi K, et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem. 2009;106(6):992–998. doi:10.1002/jcb.22078
   PubMed Web of Science ®Google Scholar
• Hayashi K, Zhao M, Yamauchi K, et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle. 2009;8(6):870–875. doi:10.4161/cc.8.6.7891
   PubMed Web of Science ®Google Scholar
• Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A. 2007;104(24):10170–10174. doi:10.1073/pnas.0703867104
   PubMed Web of Science ®Google Scholar
• Yu B, Yang M, Shi L, et al. Explicit hypoxia targeting with tumor suppression by creating an ‘obligate’ anaerobic Salmonella Typhimurium strain. Sci Rep. 2012;2(1):1–10. doi:10.1038/srep00436
   Google Scholar
• Ning BT, Yu B, Chan S, Chan JL, Huang JD, Chan GCF. Treatment of Neuroblastoma with an Engineered “Obligate” Anaerobic Salmonella typhimurium Strain YB1. J Cancer. 2017;8(9):1609–1618. doi:10.7150/jca.18776
   PubMed Web of Science ®Google Scholar
• Toley BJ, Forbes NS. Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. Integr Biol. 2012;4(2):165–176. doi:10.1039/c2ib00091a
   Google Scholar
• Kasinskas RW, Forbes NS. Salmonella typhimurium Lacking Ribose Chemoreceptors Localize in Tumor Quiescence and Induce Apoptosis. Cancer Res. 2007;67(7):3201–3209. doi:10.1158/0008-5472.CAN-06-2618
   PubMed Web of Science ®Google Scholar
• Sznol M, Lin SL, Bermudes D, Zheng L, King I. Perspective. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest. 2000;105(8):1027–1030. doi:10.1172/JCI9818
   PubMed Web of Science ®Google Scholar
• Uchugonova A, Zhao M, Zhang Y, Weinigel M, König K, Hoffman RM. Cancer-cell killing by engineered Salmonella imaged by multiphoton tomography in live mice. Anticancer Res. 2012;32(10):4331–4338.
   PubMed Web of Science ®Google Scholar
• Tu DG, Chang WW, Lin ST, Kuo CY, Tsao YT, Lee CH. Salmonella inhibits tumor angiogenesis by downregulation of vascular endothelial growth factor. Oncotarget. 2016;7(25):37513–37523. doi:10.18632/oncotarget.7038
   PubMedGoogle Scholar
• Liu F, Zhang L, Hoffman RM, Zhao M. Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle. 2010;9(22):4518–4524. doi:10.4161/cc.9.22.13744
   PubMed Web of Science ®Google Scholar
• Kuan YD, Lee CH. Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression. Oncotarget. 2016;7(1):374–385. doi:10.18632/oncotarget.6258
   PubMedGoogle Scholar
• Wang WK, Lu MF, Kuan YD, Lee CH. The treatment of mouse colorectal cancer by oral delivery tumor-targeting Salmonella. Am J Cancer Res. 2015;5(7):2222–2228.
   PubMed Web of Science ®Google Scholar
• Pizarro-Cerdá J, Cossart P. Microbe profile: listeria monocytogenes: a paradigm among intracellular bacterial pathogens. Microbiol. 2019;165(7):719–721. doi:10.1099/mic.0.000800
   PubMed Web of Science ®Google Scholar
• Radoshevich L, Cossart P. Listeria monocytogenes: towards a complete picture of its physiology and pathogenesis. Nat Rev Microbiol. 2018;16(1):32–46. doi:10.1038/nrmicro.2017.126
   PubMed Web of Science ®Google Scholar
• Pizarro-Cerdá J, Kühbacher A, Cossart P. Entry of listeria monocytogenes in mammalian epithelial cells: an updated view. Cold Spring Harb Perspect Med. 2012;2(11):a010009–a010009. doi:10.1101/cshperspect.a010009
   PubMed Web of Science ®Google Scholar
• Lambrechts A, Gevaert K, Cossart P, Vandekerckhove J, Van Troys M. Listeria comet tails: the actin-based motility machinery at work. Trends Cell Biol. 2008;18(5):220–227. doi:10.1016/j.tcb.2008.03.001
   PubMed Web of Science ®Google Scholar
• Flickinger JC, Rodeck U, Snook AE. Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress. Vaccines. 2018;6(3):48. doi:10.3390/vaccines6030048
   Web of Science ®Google Scholar
• Brocksted DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004;101(38):13832–13837. doi:10.1073/pnas.0406035101
   PubMed Web of Science ®Google Scholar
• Thompson RJ, Bouwer HGA, Portnoy DA, Frankel FR. Pathogenicity and Immunogenicity of a Listeria monocytogenes Strain That Requires d-Alanine for Growth. Infect Immun. 1998;66(8):3552–3561. doi:10.1128/IAI.66.8.3552-3561.1998
   PubMed Web of Science ®Google Scholar
• Verch T, Pan ZK, Paterson Y. Listeria monocytogenes -Based Antibiotic Resistance Gene-Free Antigen Delivery System Applicable to Other Bacterial Vectors and DNA Vaccines. Infect Immun. 2004;72(11):6418–6425. doi:10.1128/IAI.72.11.6418-6425.2004
   PubMed Web of Science ®Google Scholar
• Rayevskaya MV, Frankel FR. Systemic Immunity and Mucosal Immunity Are Induced against Human Immunodeficiency Virus Gag Protein in Mice by a New Hyperattenuated Strain of Listeria monocytogenes. J Virol. 2001;75(6):2786–2791. doi:10.1128/JVI.75.6.2786-2791.2001
   PubMed Web of Science ®Google Scholar
• Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V. Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer Immunotherapy. Clin Vaccine Immunol. 2009;16(1):96–103. doi:10.1128/CVI.00274-08
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao X, Higgins DE, Frankel FR. Conditional Lethality Yields a New Vaccine Strain of Listeria monocytogenes for the Induction of Cell-Mediated Immunity. Infect Immun. 2005;73(8):5065–5073. doi:10.1128/IAI.73.8.5065-5073.2005
   PubMed Web of Science ®Google Scholar
• Brockstedt DG, Bahjat KS, Giedlin MA, et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med. 2005;11(8):853–860. doi:10.1038/nm1276
   PubMed Web of Science ®Google Scholar
• Lauer P, Hanson B, Lemmens EE, et al. Constitutive Activation of the PrfA Regulon Enhances the Potency of Vaccines Based on Live-Attenuated and Killed but Metabolically Active Listeria monocytogenes Strains. Infect Immun. 2008;76(8):3742–3753. doi:10.1128/IAI.00390-08
   PubMed Web of Science ®Google Scholar
• Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA. Delivery of a viral antigen to the class i processing and presentation pathway by listeria monocytogenes. J Exp Med. 1994;180(6):2209–2218. doi:10.1084/jem.180.6.2209
   PubMed Web of Science ®Google Scholar
• Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, MacIag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother. 2008;57(9):1301–1313. doi:10.1007/s00262-008-0463-z
   PubMed Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters C, Pan Z-K, Wu T-C, Paterson Y. Two Listeria monocytogenes Vaccine Vectors That Express Different Molecular Forms of Human Papilloma Virus-16 (HPV-16) E7 Induce Qualitatively Different T Cell Immunity That Correlates with Their Ability to Induce Regression of Established Tumors Immortalized by HPV-16. J Immunol. 2001;167(11):6471–6479. doi:10.4049/jimmunol.167.11.6471
   PubMed Web of Science ®Google Scholar
• Sewell DA, Shahabi V, Gunn GR, Pan ZK, Dominiecki ME, Paterson Y. Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7. Cancer Res. 2004;64(24):8821–8825. doi:10.1158/0008-5472.CAN-04-1958
   PubMed Web of Science ®Google Scholar
• Schnupf P, Zhou J, Varshavsky A, Portnoy DA. Listeriolysin O Secreted by Listeria monocytogenes into the Host Cell Cytosol Is Degraded by the N-End Rule Pathway. Infect Immun. 2007;75(11):5135–5147. doi:10.1128/IAI.00164-07
   PubMed Web of Science ®Google Scholar
• Jin MP, Ng VH, Maeda S, Rest RF, Karin M. Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J Exp Med. 2004;200(12):1647–1655. doi:10.1084/jem.20041215
   PubMed Web of Science ®Google Scholar
• Wallecha A, Wood L, Pan ZK, Maciag PC, Shahabi V, Paterson Y. Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. Clin Vaccine Immunol. 2013;20(1):77–84. doi:10.1128/CVI.00488-12
   PubMed Web of Science ®Google Scholar
• Hussain SF, Paterson Y. CD4+CD25+ regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector. J Immunother. 2004;27(5):339–346. doi:10.1097/00002371-200409000-00002
   PubMed Web of Science ®Google Scholar
• Chen Z, Ozbun L, Chong N, Wallecha A, Berzofsky JA, Khleif SN. Episomal expression of truncated listeriolysin O in LmddA-LLO- E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+ FoxP3− and CD8+ T cells Zhisong. Cancer Immunol Res. 2014;2(9):911–922. doi:10.1158/2326-6066.CIR-13-0197
   PubMed Web of Science ®Google Scholar
• Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine. 2008;26(41):5315–5320. doi:10.1016/j.vaccine.2008.07.036
   PubMed Web of Science ®Google Scholar
• Wood LM, Pan ZK, Shahabi V, Paterson Y. Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy. Cancer Immunol Immunother. 2010;59(7):1049–1058. doi:10.1007/s00262-010-0830-4
   PubMed Web of Science ®Google Scholar
• Moors MA, Auerbuch V, Portnoy DA. Stability of the Listeria monocytogenes ActA protein in mammalian cells is regulated by the N-end rule pathway. Cell Microbiol. 1999;1(3):249–257. doi:10.1046/j.1462-5822.1999.00020.x
   PubMed Web of Science ®Google Scholar
• Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Effect of Histolyticus Infection and Toxin on Transplantable Mouse Tumors. Proc Soc Exp Biol Med. 1947;66(2):461–467. doi:10.3181/00379727-66-16124
   PubMed Web of Science ®Google Scholar
• Barbé S, Van Mellaert L, Theys J, et al. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett. 2005;246(1):67–73. doi:10.1016/j.femsle.2005.03.037
   PubMed Web of Science ®Google Scholar
• Liu S, Xu X, Zeng X, Li L, Chen Q, Li J. Tumor-targeting bacterial therapy: a potential treatment for oral cancer. Oncol Lett. 2014;8(6):2359–2366. doi:10.3892/ol.2014.2525
   PubMed Web of Science ®Google Scholar
• Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A. 2001;98(26):15155–15160. doi:10.1073/pnas.251543698
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Huang X, Lin J, et al. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nat Biotechnol. 2006;24(12):1573–1580. doi:10.1038/nbt1256
   PubMed Web of Science ®Google Scholar
• Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A. 2004;101(42):15172–15177. doi:10.1073/pnas.0406242101
   PubMed Web of Science ®Google Scholar
• Zhang YL, Lü R, Chang ZS, et al. Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity. Lett Appl Microbiol. 2014;59(6):580–586. doi:10.1111/lam.12322
   PubMed Web of Science ®Google Scholar
• Kaper JB, Nataro JP, Mobley HLT. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004;2(2):123–140. doi:10.1038/nrmicro818
   PubMed Web of Science ®Google Scholar
• Acs Y, Loo JFC, Yu S, Kong SK, Chan TF. Monitoring bacterial growth using tunable resistive pulse sensing with a pore-based technique. Appl Microbiol Biotechnol. 2014;98(2):855–862. doi:10.1007/s00253-013-5377-9
   PubMed Web of Science ®Google Scholar
• Kubitschek HE. Cell volume increase in Escherichia coli after shifts to richer media. J Bacteriol. 1990;172(1):94–101. doi:10.1128/jb.172.1.94-101.1990
   PubMed Web of Science ®Google Scholar
• Liu Q, Gai Y, Chen Y, Lan X, Jiang D. Escherichia coli nissle 1917 as a novel microrobot for tumor-targeted imaging and therapy. Pharmaceutics. 2021;13(8):1226. doi:10.3390/pharmaceutics13081226
   PubMed Web of Science ®Google Scholar
• Henker J, Laass M, Blokhin BM, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr. 2007;166(4):311–318. doi:10.1007/s00431-007-0419-x
   PubMed Web of Science ®Google Scholar
• Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol. 2007;297(3):151–162. doi:10.1016/j.ijmm.2007.01.008
   PubMed Web of Science ®Google Scholar
• He L, Yang H, Liu F, et al. Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth. Oncotarget. 2017;8(49):85772–85782. doi:10.18632/oncotarget.20486
   PubMedGoogle Scholar
• Zhang Y, Zhang Y, Xia L, et al. Escherichia coli Nissle 1917 targets and restrains mouse b16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol. 2012;78(21):7603–7610. doi:10.1128/AEM.01390-12
   PubMed Web of Science ®Google Scholar
• Zschüttig A, Auerbach C, Meltke S, et al. Complete Sequence of Probiotic Symbioflor 2 Escherichia coli Strain G3/10 and Draft Sequences of Symbioflor 2 E. coli Strains G1/2, G4/9, G5, G6/7, and G8. Genome Announc. 2015;3(2):9–10. doi:10.1128/genomeA.01330-14
   Google Scholar
• Kocijancic D, Felgner S, Frahm M, et al. Therapy of solid tumors using probiotic Symbioflor-2-restraints and potential. Oncotarget. 2016;7(16):22605–22622. doi:10.18632/oncotarget.8027
   PubMedGoogle Scholar
• Zhu J, Ke Y, Liu Q, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466. doi:10.1038/s41467-022-35130-7
   PubMed Web of Science ®Google Scholar
• Kaczmarek K, Więckiewicz J, Węglarczyk K, Siedlar M, Baran J. The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer. Cancers. 2021;13(12):3004. doi:10.3390/cancers13123004
   PubMed Web of Science ®Google Scholar
• Heydari Z, Rahaie M, Alizadeh AM, Agah S, Khalighfard S, Bahmani S. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b, 26b, 18a and 155, and Their Involving Genes in Mice Colon Cancer. Probiotics Antimicrob Proteins. 2019;11(4):1155–1162. doi:10.1007/s12602-018-9478-8
   PubMed Web of Science ®Google Scholar
• Huter V, Szostak MP, Gampfer J, et al. Bacterial ghosts as drug carrier and targeting vehicles. J Control Release. 1999;61(1–2):51–63. doi:10.1016/S0168-3659(99)00099-1
   PubMed Web of Science ®Google Scholar
• Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The bacterial ghost platform system: production and applications. Bioeng Bugs. 2010;1(5):326–336. doi:10.4161/bbug.1.5.12540
   PubMedGoogle Scholar
• Hajam IA, Dar PA, Appavoo E, Kishore S, Bhanuprakash V, Ganesh K. Bacterial ghosts of Escherichia coli drive efficient maturation of bovine monocyte-derived dendritic cells. PLoS One. 2015;10(12):1–15. doi:10.1371/journal.pone.0144397
   Web of Science ®Google Scholar
• Kraśko JA, Źilionyte K, Darinskas A, et al. Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. Oncol Rep. 2017;37(1):171–178. doi:10.3892/or.2016.5252
   PubMed Web of Science ®Google Scholar
• Parti RP, Biswas D, Wang M, Liao M, Dillon JAR. A MinD mutant of enterohemorrhagic E. coli O157:H7 has reduced adherence to human epithelial cells. Microb Pathog. 2011;51(5):378–383. doi:10.1016/j.micpath.2011.07.003
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Brahmbhatt H. Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Curr Opin Biotechnol. 2011;22(6):909–916. doi:10.1016/j.copbio.2011.04.008
   PubMed Web of Science ®Google Scholar
• Farley MM, Hu B, Margolin W, Liu J, de Boer P. Minicells, back in fashion. J Bacteriol. 2016;198(8):1186–1195. doi:10.1128/JB.00901-15
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol. 2009;27(7):643–651. doi:10.1038/nbt.1547
   PubMed Web of Science ®Google Scholar
• Shubhika K. Nanotechnology and medicine - The upside and the downside. Int J Drug Dev Res. 2013;5:1–10.
   Google Scholar
• Nguyen HN, Romero Jovel S, Nguyen THK. Nanosized Minicells Generated by Lactic Acid Bacteria for Drug Delivery. J Nanomater. 2017;2017:1–10. doi:10.1155/2017/6847297
   Web of Science ®Google Scholar
• Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4(3):95–99. doi:10.1186/bcr432
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Desai J, Rosenthal M, et al. A First-Time-In-Human Phase i Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. PLoS One. 2015;10(12):1–17. doi:10.1371/journal.pone.0144559
   Web of Science ®Google Scholar
• MacDiarmid JA, Langova V, Bailey D, et al. Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS One. 2016;11(4):1–23. doi:10.1371/journal.pone.0151832
   Web of Science ®Google Scholar
• Zhang Y, Ji W, He L, et al. E. coli Nissle 1917-Derived Minicells for Targeted Delivery of Chemotherapeutic Drug to Hypoxic Regions for Cancer Therapy. Theranostics. 2018;8(6):1690–1705. doi:10.7150/thno.21575
   PubMed Web of Science ®Google Scholar
• Chatterjee SN, Das J. Electron Microscopic Observations on the Excretion of Cell-wall Material. J Gen Microbiol. 1967;49(1):1–11. doi:10.1099/00221287-49-1-1
   PubMedGoogle Scholar
• Toyofuku M, Nomura N, Eberl L. Types and origins of bacterial membrane vesicles. Nat Rev Microbiol. 2019;17(1):13–24. doi:10.1038/s41579-018-0112-2
   PubMed Web of Science ®Google Scholar
• Gujrati V, Kim S, Kim SH, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 2014;8(2):1525–1537. doi:10.1021/nn405724x
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao R, Cheng K, et al. Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition. ACS Nano. 2020;14(12):16698–16711. doi:10.1021/acsnano.0c03776
   PubMed Web of Science ®Google Scholar
• Santos JC, Dick MS, Lagrange B, et al. LPS targets host guanylate-binding proteins to the bacterial outer membrane for non-canonical inflammasome activation. EMBO J. 2018;37(6):1–19. doi:10.15252/embj.201798089
   PubMed Web of Science ®Google Scholar
• Dorward DW, Garon CF. DNA is packaged within membrane-derived vesicles of gram-negative but not gram-positive bacteria. Appl Environ Microbiol. 1990;56(6):1960–1962. doi:10.1128/aem.56.6.1960-1962.1990
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fang Z, Li R, Huang X, Liu Q. Design of outer membrane vesicles as cancer vaccines: a new toolkit for cancer therapy. Cancers. 2019;11(9):1–24. doi:10.3390/cancers11091314
   Web of Science ®Google Scholar
• Blakemore R. Magnetotactic bacteria. Science. 1975;190(4212):377–379. doi:10.1126/science.170679
   PubMed Web of Science ®Google Scholar
• Dieudonné A, Pignol D, Prévéral S. Magnetosomes: biogenic iron nanoparticles produced by environmental bacteria. Appl Microbiol Biotechnol. 2019;103(9):3637–3649. doi:10.1007/s00253-019-09728-9
   PubMed Web of Science ®Google Scholar
• Farina M, Esquivel DMS, de Barros HGPL. Magnetic iron-sulphur crystals from a magnetotactic microorganism. Nature. 1990;343(6255):256–258. doi:10.1038/343256a0
   Web of Science ®Google Scholar
• Frankel RB, Blakemore RP, Wolfe RS. Magnetite in freshwater magnetotactic bacteria. Science. 1979;203(4387):1355–1356. doi:10.1126/science.203.4387.1355
   PubMed Web of Science ®Google Scholar
• Lisjak D, Mertelj A. Anisotropic magnetic nanoparticles: a review of their properties, syntheses and potential applications. Prog Mater Sci. 2018;95:286–328.
   Web of Science ®Google Scholar
• Yang W, Bai Y, Wang X, Dong X, Li Y, Fang M. Attaching biosynthesized bacterial magnetic particles to polyethylenimine enhances gene delivery into mammalian cells. J Biomed Nanotechnol. 2016;12(4):789–799. doi:10.1166/jbn.2016.2213
   PubMed Web of Science ®Google Scholar
• Mériaux S, Boucher M, Marty B, et al. Magnetosomes, Biogenic Magnetic Nanomaterials for Brain Molecular Imaging with 17.2 T MRI Scanner. Adv Healthc Mater. 2015;4(7):1076–1083. doi:10.1002/adhm.201400756
   PubMed Web of Science ®Google Scholar
• Orlando T, Mannucci S, Fantechi E, et al. Characterization of magnetic nanoparticles from Magnetospirillum Gryphiswaldense as potential theranostics tools. Contrast Media Mol Imaging. 2016;11(2):139–145. doi:10.1002/cmmi.1673
   PubMed Web of Science ®Google Scholar
• Erdal E, Demirbilek M, Yeh Y, et al. A Comparative Study of Receptor-Targeted Magnetosome and HSA-Coated Iron Oxide Nanoparticles as MRI Contrast-Enhancing Agent in Animal Cancer Model. Appl Biochem Biotechnol. 2018;185(1):91–113. doi:10.1007/s12010-017-2642-x
   PubMed Web of Science ®Google Scholar
• Alphandéry E, Idbaih A, Adam C, et al. Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field. J Control Release. 2017;262:259–272. doi:10.1016/j.jconrel.2017.07.020
   PubMed Web of Science ®Google Scholar
• Long R, Liu Y, Dai Q, Wang S, Deng Q, Zhou X. A natural bacterium-produced membrane-bound nanocarrier for drug combination therapy. Materials. 2016;9(11):1–10. doi:10.3390/ma9110889
   Web of Science ®Google Scholar
• Wang X, Wang J, Geng Y, et al. An enhanced anti-tumor effect of apoptin-cecropin B on human hepatoma cells by using bacterial magnetic particle gene delivery system. Biochem Biophys Res Commun. 2018;496(2):719–725. doi:10.1016/j.bbrc.2018.01.108
   PubMed Web of Science ®Google Scholar
• Dai Q, Long R, Wang S, et al. Bacterial magnetosomes as an efficient gene delivery platform for cancer theranostics. Microb Cell Fact. 2017;16(1):1–9. doi:10.1186/s12934-017-0830-6
   PubMedGoogle Scholar
• Pum D, Toca-Herrera JL, Sleytr UB. S-Layer protein self-assembly. Int J Mol Sci. 2013;14(2):2484–2501. doi:10.3390/ijms14022484
   PubMed Web of Science ®Google Scholar
• Stel B, Cometto F, Rad B, De Yoreo JJ, Lingenfelder M. Dynamically resolved self-assembly of S-layer proteins on solid surfaces. Chem Commun. 2018;54(73):10264–10267. doi:10.1039/C8CC04597F
   PubMed Web of Science ®Google Scholar
• Ilk N, Egelseer EM, Sleytr UB. S-layer fusion proteins-construction principles and applications. Curr Opin Biotechnol. 2011;22(6):824–831. doi:10.1016/j.copbio.2011.05.510
   PubMed Web of Science ®Google Scholar
• Wetzer B, Pum D, Sleytr UB. S-layer stabilized solid supported lipid bilayers. J Struct Biol. 1997;119(2):123–128. doi:10.1006/jsbi.1997.3867
   PubMed Web of Science ®Google Scholar
• Farjadian F, Moghoofei M, Mirkiani S, et al. Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: set the bugs to work? Biotechnol Adv. 2018;36(4):968–985. doi:10.1016/j.biotechadv.2018.02.016
   PubMed Web of Science ®Google Scholar
• Shi H, Chen L, Liu Y, et al. Bacteria-Driven Tumor Microenvironment-Sensitive Nanoparticles Targeting Hypoxic Regions Enhances the Chemotherapy Outcome of Lung Cancer. International Journal of Nanomedicine. 2023;18:1299–1315. doi:10.2147/IJN.S396863
   PubMed Web of Science ®Google Scholar
• Li J, Dai J, Zhao L, et al. Bioactive Bacteria/MOF Hybrids Can Achieve Targeted Synergistic Chemotherapy and Chemodynamic Therapy against Breast Tumors. Adv Funct Mater. 2023;33(42):2303254. doi:10.1002/adfm.202303254
   Web of Science ®Google Scholar
• Xiao S, Shi H, Zhang Y, et al. Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer. J Nanobiotechnol. 2022;20(1):178. doi:10.1186/s12951-022-01373-1
   PubMed Web of Science ®Google Scholar
• Li Y, Leng Q, Zhang Y, et al. Anaerobic bacteria mediated ‘smart missile’ targeting tumor hypoxic area enhances the therapeutic outcome of lung cancer. Chem Eng J. 2022;438:135566. doi:10.1016/j.cej.2022.135566
   Web of Science ®Google Scholar
• Chen Q, Bai H, Wu W, et al. Bioengineering Bacterial Vesicle-Coated Polymeric Nanomedicine for Enhanced Cancer Immunotherapy and Metastasis Prevention. Nano Lett. 2020;20(1):11–21. doi:10.1021/acs.nanolett.9b02182
   PubMed Web of Science ®Google Scholar
• Kuerban K, Gao X, Zhang H, et al. Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer. Acta Pharm Sin B. 2020;10(8):1534–1548. doi:10.1016/j.apsb.2020.02.002
   PubMed Web of Science ®Google Scholar
• Patyar S, Joshi R, Byrav DSP, Prakash A, Medhi B, Das BK. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci. 2010;17(1):1–9. doi:10.1186/1423-0127-17-21
   PubMed Web of Science ®Google Scholar
• Xie S, Zhao L, Song X, Tang M, Mo C, Li X. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. J Control Release. 2017;268:390–399. doi:10.1016/j.jconrel.2017.10.041
   PubMed Web of Science ®Google Scholar
• Quispe-Tintaya W, Chandra D, Jahangir A, et al. Nontoxic radioactive Listeria at is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(21):8668–8673. doi:10.1073/pnas.1211287110
   PubMed Web of Science ®Google Scholar
• Chandra D, Selvanesan BC, Yuan Z, et al. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget. 2017;8(13):20729–20740. doi:10.18632/oncotarget.15117
   PubMed Web of Science ®Google Scholar
• Li X, Lovell JF, Yoon J, Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17(11):657–674. doi:10.1038/s41571-020-0410-2
   PubMed Web of Science ®Google Scholar
• Qing S, Lyu C, Zhu L, et al. Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy. Adv Mater. 2020;32:1–14.
   Web of Science ®Google Scholar
• Chen W, Wang Y, Qin M, et al. Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy. ACS Nano. 2018;12(6):5995–6005. doi:10.1021/acsnano.8b02235
   PubMed Web of Science ®Google Scholar
• Gujrati V, Prakash J, Malekzadeh-Najafabadi J, et al. Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging. Nat Commun. 2019;10(1):1–10. doi:10.1038/s41467-019-09034-y
   PubMedGoogle Scholar
• Chen QW, Liu XH, Fan JX, et al. Self-Mineralized Photothermal Bacteria Hybridizing with Mitochondria-Targeted Metal–Organic Frameworks for Augmenting Photothermal Tumor Therapy. Adv Funct Mater. 2020;30. doi:10.1002/adfm.201909806
   Web of Science ®Google Scholar
• Zhuang Q, Xu J, Deng D, et al. Bacteria-derived membrane vesicles to advance targeted photothermal tumor ablation. Biomaterials. 2021;268:120550. doi:10.1016/j.biomaterials.2020.120550
   PubMed Web of Science ®Google Scholar
• Zheng DW, Chen Y, Li ZH, et al. Optically-controlled bacterial metabolite for cancer therapy. Nat Commun. 2018;9(1):1–12. doi:10.1038/s41467-018-03233-9
   PubMedGoogle Scholar
• Luo Y, Xu D, Gao X, et al. Nanoparticles conjugated with bacteria targeting tumors for precision imaging and therapy. Biochem Biophys Res Commun. 2019;514(4):1147–1153. doi:10.1016/j.bbrc.2019.05.074
   PubMed Web of Science ®Google Scholar
• Wang H, Chen T, Wan L, et al. Attenuated Salmonella engineered with an apoptosis-inducing factor (AIF) eukaryotic expressing system enhances its anti-tumor effect in melanoma in vitro and in vivo. Appl Microbiol Biotechnol. 2020;104(8):3517–3528. doi:10.1007/s00253-020-10485-3
   PubMed Web of Science ®Google Scholar
• Mateos-Chávez AA, Muñoz-López P, Becerra-Báez EI, et al. Live Attenuated Salmonella enterica Expressing and Releasing Cell-Permeable Bax BH3 Peptide Through the MisL Autotransporter System Elicits Antitumor Activity in a Murine Xenograft Model of Human B Non-hodgkin’s Lymphoma. Front Immunol. 2019;10:1–22. doi:10.3389/fimmu.2019.02562
   PubMed Web of Science ®Google Scholar
• Samadi M, Majidzadeh-a K, Salehi M, et al. Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo. J Biol Eng. 2021;2:1–15.
   Google Scholar
• Huang W, Shu C, Hua L, et al. Modified bacterial outer membrane vesicles induce autoantibodies for tumor therapy. Acta Biomater. 2020;108:300–312. doi:10.1016/j.actbio.2020.03.030
   PubMed Web of Science ®Google Scholar
• Swofford CA, Van Dessel N, Forbes NS. Quorum-sensing Salmonella selectively trigger protein expression within tumors. Proc Natl Acad Sci USA. 2015;112(11):3457–3462. doi:10.1073/pnas.1414558112
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable Bacteria Induce Durable Tumor Regression and Systemic Antitumor Immunity. Nat Med. 2019;25(7):1057–1063. doi:10.1038/s41591-019-0498-z
   PubMed Web of Science ®Google Scholar
• Yaghoubi A, Khazaei M, Jalili S, et al. Bacteria as a Double-Action Sword in Cancer. Biochim Biophys Acta Rev Cancer. 2020;1874:188388.
   PubMed Web of Science ®Google Scholar
• Li J, Zakariah M, Malik A, et al. Analysis of Salmonella Typhimurium Protein-Targeting in the Nucleus of Host Cells and the Implications in Colon Cancer: an in-Silico Approach. Infect Drug Resist. 2020;13:2433–2442.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng W, Yang K. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020;217(5):e20192282. doi:10.1084/jem.20192282
   PubMed Web of Science ®Google Scholar
• Lee SH, Cho SY, Yoon Y, et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat Microbiol. 2021;6(3):277–288. doi:10.1038/s41564-020-00831-6
   PubMed Web of Science ®Google Scholar
• Xie S, Zhang P, Zhang Z, et al. Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release. Acta Biomater. 2021;131:172–184. doi:10.1016/j.actbio.2021.06.030
   PubMed Web of Science ®Google Scholar
• Toso JF, Gill VJ, Hwu P, et al. Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma. J Clin Oncol. 2002;20(1):142–152. doi:10.1200/JCO.2002.20.1.142
   PubMed Web of Science ®Google Scholar
• Gniadek TJ, Augustin L, Schottel J, et al. A Phase I, dose escalation, single dose trial of oral attenuated salmonella typhimurium containing human IL-2 in patients with metastatic gastrointestinal cancers. J Immunother. 2020;43(7):217–221. doi:10.1097/CJI.0000000000000325
   PubMedGoogle Scholar
• Le DT, Brockstedt DG, Nir-Paz R, et al. A Live-attenuated Listeria Vaccine (ANZ-100) and a Live- attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase 1 Studies of Safety and Immune Induction. Clin Cancer Res. 2012;18:858–868.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes –Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. J Clin Oncol. 2015;33(12):1325–1333. doi:10.1200/JCO.2014.57.4244
   PubMed Web of Science ®Google Scholar
• Le DT, Picozzi VJ, Ko AH, et al. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019;25(18):5493–5502. doi:10.1158/1078-0432.CCR-18-2992
   PubMed Web of Science ®Google Scholar
• Hassan R, Alley E, Kindler H, et al. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019;25(19):5787–5798. doi:10.1158/1078-0432.CCR-19-0070
   PubMed Web of Science ®Google Scholar
• Karbach J, Neumann A, Brand K, et al. Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley’s Toxins) in Patients with NY-ESO-1 Expressing Cancers: immunological Effects and Clinical ActivityEffects of Mixed Bacterial Vaccine. Clin Cancer Res. 2012;18(19):5449–5459. doi:10.1158/1078-0432.CCR-12-1116
   PubMed Web of Science ®Google Scholar
• Steinberg GD, Shore ND, Karsh LI. Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC). J Clin Oncol. 2017;35(15_suppl):4531. doi:10.1200/JCO.2017.35.15_suppl.4531
   Google Scholar
• Drake CG, Pachynski RK, Subudhi SK, et al. Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(2):219–228. doi:10.1038/s41391-021-00402-8
   PubMed Web of Science ®Google Scholar
• Janku F, Zhang HH, Pezeshki A, et al. Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. Clin Cancer Res. 2021;27(1):96–106. doi:10.1158/1078-0432.CCR-20-2065
   PubMed Web of Science ®Google Scholar
• Lucca I, Derré L, Cesson V, et al. Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile. Eur Urol Open Sci. 2022;45:55–58. doi:10.1016/j.euros.2022.09.004
   PubMedGoogle Scholar
• Zhao AZ, Li F, Mai J, et al. Effects of oncolytic bacteria, SGN1, against a broad spectrum of malignancies in pre-clinical and clinical studies. J Clin Oncol. 2023;41(16_suppl):e15184. doi:10.1200/JCO.2023.41.16_suppl.e15184
   Web of Science ®Google Scholar
• Liu C, Han Y, Kankala R, Wang S, Chen A. Subcellular Performance of Nanoparticles in Cancer Therapy. Int J Nanomed. 2020;15:675–704. doi:10.2147/IJN.S226186
   PubMed Web of Science ®Google Scholar
• Forbes NS, Coffin RS, Deng L, et al. White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer. 2018;6(1):1–24. doi:10.1186/s40425-018-0381-3
   PubMedGoogle Scholar
• Gurbatri CR, Lia I, Vincent R, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020;12(530). doi:10.1126/scitranslmed.aax0876
   PubMed Web of Science ®Google Scholar
• Kim OY, Dinh NTH, Park HT, Choi SJ, Hong K, Gho YS. Bacterial protoplast-derived nanovesicles for tumor targeted delivery of chemotherapeutics. Biomaterials. 2017;113:68–79. doi:10.1016/j.biomaterials.2016.10.037
   PubMed Web of Science ®Google Scholar
• Aly RG, El-Enbaawy MI, Abd El-Rahman SS, Ata NS. Antineoplastic activity of Salmonella Typhimurium outer membrane nanovesicles. Exp Cell Res. 2021;399(1):112423. doi:10.1016/j.yexcr.2020.112423
   PubMed Web of Science ®Google Scholar
• Gao J, Wang S, Dong X, Wang Z. RGD-expressed bacterial membrane-derived nanovesicles enhance cancer therapy via multiple tumorous targeting. Theranostics. 2021;11(7):3301–3316. doi:10.7150/thno.51988
   PubMed Web of Science ®Google Scholar
• Kaczmarek K, Więckiewicz J, Węglarczyk K, Siedlar M, Baran J. The anti-tumor effect of Lactococcus lactis bacteria-secreting human soluble trail can be enhanced by metformin both in vitro and in vivo in a mouse model of human colorectal cancer. Cancers. 2021;13(12):1–25.
   Web of Science ®Google Scholar
• Boucher M, Geffroy F, Prévéral S, et al. Genetically tailored magnetosomes used as MRI probe for molecular imaging of brain tumor. Biomaterials. 2017;121:167–178. doi:10.1016/j.biomaterials.2016.12.013
   PubMed Web of Science ®Google Scholar